Key insights
- InvestingPro's fair value analysis flagged Tempus AI (TEM) as overvalued in December 2025, predicting a 39% decline. The stock subsequently fell by a similar amount. This highlights the potential of valuation models to identify overpriced stocks, but the impact on the broader US market is limited.
When Tempus AI, Inc. (NASDAQ:TEM) was trading at $76.66 in early December 2025, InvestingPro’s Fair Value analysis flagged a significant warning: the healthcare AI stock was overvalued by nearly 39%. Over the following four months, that prediction proved remarkably accurate as shares plummeted 39% to $46.79, closely approaching the Fair Value target of $47.08. This case demonstrates how Fair Value analysis helps investors identify overpriced stocks, find better entry and exit points, and make more informed decisions by combining multiple valuation methodologies to determine a stock’s intrinsic worth. Investors seeking current opportunities can explore the most overvalued list for stocks that may face similar headwinds.
Tempus AI operates in the precision medicine sector, leveraging artificial intelligence to analyze clinical and molecular data for cancer care and other diseases. When InvestingPro’s Fair Value models identified the mispricing on December 6, 2025, the company reported revenue of $1.11 billion but remained unprofitable with EBITDA of -$171.14 million and earnings per share of -$1.19. The stock had experienced extreme volatility in the preceding six months, including a 34% surge in August followed by consecutive monthly declines of 13% and 24% in November and December.
At $76.66, InvestingPro’s analysis indicated the stock was trading at a 38.6% premium to its intrinsic value of $47.08. The Fair Value calculation, which aggregates discounted cash flow models, comparable company analyses, and analyst consensus targets, suggested significant downside risk. Despite the company’s innovative technology platform and partnerships with major pharmaceutical companies, the valuation simply didn’t align with the fundamentals of an unprofitable, recently public company.
The subsequent price action validated InvestingPro’s assessment with striking precision. Shares declined 24% in December, briefly recovered 1.3% in January, then resumed falling with an 11% drop in February and a 15% decline in March. By late March 2026, the stock traded at $46.79—just 2 cents above the Fair Value target and representing a 39% decline from the identification point. This accuracy showcases the power of systematic valuation analysis, similar to the track record demonstrated by InvestingPro’s AI-powered ProPicks, which have consistently outperformed the market.
Interestingly, the decline occurred despite seemingly positive developments. Cathie Wood’s ARK Investment Management made multiple purchases of Tempus AI shares, and the company announced partnerships with Merck, launched new cancer detection algorithms, and achieved record contract value of $1.1 billion. However, these catalysts couldn’t overcome valuation concerns. Analyst firm Stifel cut its price target to $60 citing valuation, while CEO Eric Lefkofsky sold millions of dollars in stock. Current fundamentals show revenue increased to $1.27 billion, but losses deepened with EPS falling to -$1.41, reinforcing the original Fair Value assessment.
InvestingPro’s Fair Value methodology works by calculating intrinsic worth through multiple approaches including discounted cash flow analysis, which projects future cash flows and discounts them to present value, comparable company analysis that benchmarks against industry peers, and consensus analyst targets. By aggregating these methods and incorporating a margin of safety, Fair Value provides investors with a comprehensive view of whether a stock is trading above or below its true worth—critical information for avoiding overvalued positions like Tempus AI in December 2025.
For investors seeking to identify similar opportunities—whether overvalued stocks to avoid or undervalued gems to purchase—InvestingPro offers real-time Fair Value analysis across thousands of stocks, along with ProTips, financial health scores, and comprehensive fundamental data. Learn more about InvestingPro to access the tools that successfully identified Tempus AI’s overvaluation months before the decline materialized.